Receptor-interacting protein kinase-3 (RIPK3): a new biomarker for necrotising enterocolitis in preterm infants
Topic overview
This study identifies RIPK3 as a novel plasma biomarker for diagnosing necrotising enterocolitis in preterm infants, with superior performance when combined with lactic acid and CRP. RIPK3 levels correlate with disease severity and predict time to full enteral feeding post-recovery, offering clinicians a tool for both diagnosis and feeding management decisions.
Key takeaways
- Plasma RIPK3 levels correlate with NEC severity in preterm infants, with stage III NEC showing mean levels of 32.37 ng/mL.
- Combined RIPK3, lactic acid, and CRP testing achieves 0.925 ROC AUC for NEC diagnosis, superior to individual markers.
- RIPK3 levels ≥20.06 ng/mL predict longer time to full enteral feeding post-NEC, guiding feeding advancement strategies.
- RIPK3 serves as a novel biomarker for both diagnostic and prognostic assessment in neonatal necrotizing enterocolitis.
- This multi-biomarker approach may enable earlier NEC detection and risk stratification in vulnerable preterm populations.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Receptor-interacting protein kinase-3 (RIPK3): a new biomarker for necrotising enterocolitis in preterm infants. GlobalCastMD Medical Library. 2024-05-02. https://dev.library.globalcastmd.com/article/8561?via_space=staycurrentmd
Comments